GlassScriptPhysician profile
Kara M Conti
NPI 1861665291
$2,608.73
in general payments reported to CMS, 2019-2025
31 companies · $296 in 2025
The $296 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $411 · 2020: $308 · 2021: $391 · 2022: $395 · 2023: $598 · 2024: $210 · 2025: $296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,103.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $442.53 | 2019-2023 | Lo Loestrin Fe |
| Roche Diagnostics Corporation | $187.11 | 2019-2021 | |
| Astellas Pharma US INC | $180.96 | 2019-2025 | Veozah, Myrbetriq |
| Hologic Sales and Service, LLC | $169.66 | 2019-2025 | Aptima |
| Bayer Healthcare Pharmaceuticals INC. | $142.75 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $136.63 | 2022-2023 | |
| Shield Therapeutics INC | $125.17 | 2022-2025 | Accrufer |
| Sumitomo Pharma America, INC. | $111.45 | 2023-2024 | Gemtesa, Myfembree |
| Organon LLC | $99.29 | 2022-2025 | Nexplanon, Jada System |
| Coopersurgical, INC. | $97.39 | 2019-2025 | Endosee |
| Therapeuticsmd, INC. | $93.07 | 2019-2022 | |
| Mylan Pharmaceuticals INC. | $93.07 | 2020-2022 | |
| Amgen INC. | $86.58 | 2019-2020 | |
| Scynexis, INC. | $79.13 | 2022 | |
| Urovant Sciences INC | $67.88 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $64.65 | 2022-2023 | |
| Novo Nordisk INC | $64.52 | 2023-2024 | Wegovy |
| Baxter Healthcare | $40.47 | 2025 | Perclot |
| Exeltis, USA INC. | $39.82 | 2022-2023 | Slynd |
| Intuitive Surgical, INC. | $39.10 | 2023 | Da Vinci Surgical System |
| Sage Therapeutics, LLC | $33.18 | 2025 | Zurzuvae |
| Agile Therapeutics, INC. | $30.48 | 2021 | |
| Merck Sharp & Dohme LLC | $30.04 | 2019 | |
| Pharmacosmos Therapeutics INC. | $28.71 | 2025 | Monoferric |
| Amag Pharmaceuticals, INC. | $26.28 | 2019 | |
| Exact Sciences Corporation | $21.31 | 2025 | The Cologuard Plus Collection Kit |
| Monaghan Medical Corporation | $18.06 | 2023 | Aerochamber |
| Ethicon US, LLC | $17.37 | 2022 | |
| Meditrina | $16.14 | 2022 | |
| Axonics, INC. | $14.70 | 2023 | Axonics |
| Lupin INC. | $11.23 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kara Conti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.